Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations
| Brand name | CLINDAMYCIN PHOSPHATE |
| Generic name | CLINDAMYCIN PHOSPHATE |
| Active ingredient(s) | CLINDAMYCIN PHOSPHATE |
| Distributed by / for | Baxter Healthcare Corporation |
| NDC | 43066-995-24 |
| Full product label | Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Manufactured by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 43066-995-24. |
| Recalling firm | Baxter Healthcare Corporation |
| Distribution | US Nationwide; Puerto Rico; and Chile. |
| Quantity | N/A |
| Recall initiated | 2026-08-06 |
| Report date | 2026-09-09 |
| Recall completed | — |
| Recall number | D-0818-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Deerfield IL United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗